"NOMIS is all about enabling outstanding talent to take on high-risk research."
- Georg Heinrich “Heini” Thyssen, NOMIS Founder
Home / News / Karl Deisseroth: No implants needed for precise control deep into the brain

Karl Deisseroth: No implants needed for precise control deep into the brain

NOMIS Awardee Karl Deisseroth and colleagues have demonstrated behavioral modulation without surgery, enabling implant-free deep brain optogenetics. The research was published on Oct. 5, 2020, in Nature Biotechnology.

Optogenetics can now control neural circuits at unprecedented depths within living brain tissue without surgery

By Megan Scudellari

Karl Deisseroth

The first time Karl Deisseroth used light to control brain cells in a dish, people had a lot of questions, three in particular. Can the technique be used in living animals? Can it target different cell types? Can it work without implanting a light source into the brain?

In the years since that initial groundbreaking 2004 experiment, Deisseroth’s team and others found the answers to the first two questions: yes and yes. This month they answered the third question with another yes, successfully introducing an implant-free version of the technique. It is the first demonstration that optogenetics—which uses a combination of light and genetic engineering to control brain cells—can accurately switch the cells on and off without surgery.

“This is kind of a nice bookend to 16 years of research,” says Deisseroth, a neuroscientist and bioengineer at Stanford University. “It took years and years for us to sort out how to make it work.” The result is described this month in the journal Nature Biotechnology.

Optogenetics involves genetically engineering animal brains to express light-sensitive proteins—called opsins—in the membranes of neurons. The opsins’ reactions to pulses of light can either induce a neuron to “fire” or suppress its ability to fire. Optogenetics has been used to map brain pathways, identify how complex behaviors are regulated, create false memories in mice, and much more. It’s also been used to develop an optogenetic pacemaker, among other technologies.

A new, non-invasive technique turned on these brain cells (serotonergic dorsal raphe cells) with millisecond-precision. (Photo: Ritchie Chen and Karl Deisseroth)

Most of the time, getting the pulses of light inside the brain to control cells has required invasive implants: from tethered optical fibers, to peppercorn-sized wireless implants, to stretchy spinal implants.

In April, Guoping Feng and colleagues at MIT, along with Deisseroth, demonstrated a minimally invasive optogenetic system that required drilling a small hole in the skull, then being able to control opsin-expressing neurons six millimeters deep into the brain using blue light. This approach used of a type of opsin that slowly activates neurons in a step-wise manner.

In the most recent study, Deisseroth and colleagues sought to instead enable both deep and fast optogenetics without surgery. The Stanford team expressed in the brain cells of mice a powerful new opsin called ChRmine (pronounced like the deep-red color “carmine”), discovered by Deisseroth’s group last year in a marine organism. Then, they shined a red light outside the skull and were able to activate neural circuits in the midbrain and brainstem at depths of up to 7 millimeters. With the technique, the scientists turned on and off brain circuits with millisecond precision. “It really worked well, far better than we even expected might be possible,” says Deisseroth.

The team then tested the effectiveness of the system. In one instance, they used light to quickly and precisely stop seizures in epileptic mice, and in another to turn on serotonin-producing neurons to promote social behavior in mice.

Most optogenetic techniques involve injecting viruses with an opsin gene of choice directly into the brain with a needle. To avoid this, the Stanford team used a type of PHP virus developed at CalTech that can be injected in the blood. The virus then crosses the blood-brain barrier to deliver its payload, an opsin gene, to brain cells. In this case, even the delivery of the gene is noninvasive—no needle penetrates the brain.

Deisseroth’s team is now testing the non-invasive technique in fish and collaborating with others to apply it to non-human primates. They’re also working with the Seattle-based Allen Institute to develop mouse lines bred with ChRmine in their cells. “We hope these will be a broadly available and applicable research tool,” says Deisseroth. “We’re just excited to share this capability with everybody.”

Go to this IEEE Spectrum article

Read the Nature Biotechnology publication


NOMIS Project(s)


NOMIS Researchers

D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences
Stanford Medicine
Send via Email
Share on Linkedin